Ultimele actualizari :
28/03/2015
Stabilitatea si compatibilitatea medicamentelor
Bine ati venit pe site-ul Stabilis. Daca doriti sa primiti ultimele noutati, trimiteti-ne adresa mail.

Pentru intrebari sau comentarii, contactati stabilis@wanadoo.fr
Baze de date  
Bibiografie : 1987
Molecula (substanta activa) : 685
Clasa farmacologica : 40
Stabilitatea solutiilor : 4165
Stabilitatea in amestec : 941
Incompatibilitati : 2556
Denumirea comerciala : 1930
Noutati - Molecula (substanta activa)  
Citostatic Injectabil Blinatumomab 01/03/2015
Citostatic Injectabil Vincristine sulfate liposome 01/03/2015
Citostatic Injectabil Pembrolizumab 01/03/2015
Citostatic Injectabil Omacetaxine mepesuccinate 01/03/2015
Antibiotic Injectabil Oritavancin 01/03/2015
Imunosupresor Injectabil Siltuximab 01/03/2015
Citostatic Injectabil Ramucirumab 01/03/2015
Vitamina Soluţie orală Pyridoxine hydrochloride 17/02/2015
Diverse Soluţie orală Ursodesoxycholique acid 17/02/2015
Diverse Aerosol Citric acid 11/12/2014
Diverse Soluţie orală Cilazapril 11/12/2014
Diverse Colir Infliximab 11/12/2014
Anxiolitic Injectabil Lormetazepam 01/12/2014
Antibiotic Injectabil Dalbavancin 30/11/2014
Diverse Injectabil Sodium oxybate 30/11/2014
Antibiotic Injectabil Tedizolid 30/11/2014
Diverse Injectabil Conivaptan 23/11/2014
Citostatic Injectabil Obinutuzumab 23/11/2014
Citostatic Injectabil Belinostat 23/11/2014
Diverse Injectabil Metaraminol 23/11/2014
Noutati - Bibiografie  
Data de intrare
3787 Oritavancin diphosphate (Orbactiv®) - Summary of Product Characteristics The Medicines Company 16/01/2015
3771 Pembrolizumab (Keytruda®) - Summary of Product Characteristics Merck Sharp Dohme 22/12/2014
3772 Siltuximab (Sylvant®) - Summary of Product Characteristics Janssen Biotech 22/12/2014
3773 Ramicirumab (Cyramza®) - Summary of Product Characteristics Eli Lilly 22/12/2014
3774 Blinatumomab - (Blincyto®) - Summary of Product Characteristics 22/12/2014
3775 Vincristine sulfate liposome injection (Marqibo®) - Summary of Product Characteristics Talon Therapeutics 22/12/2014
3776 Omecetaxine (Synribo®) - Summary of Product Characteristics Teva Pharmaceuticals 22/12/2014
3779 Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection Am J Health-Syst Pharm 22/12/2014
3782 ­Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration Int J Pharm 22/12/2014
3786 Stability of Melphalan Solution for Intravitreal Injection for Retinoblastoma JAMA Ophtalmology 22/12/2014
3770 Phenylephrine hydrochloride (Vazculep® - Summary of Product Characteristics) Eclat Pharmaceuticals 21/12/2014
3768 Obnituzumab (Gazyvaro®) - Summary of Product Characteristics Roche Products Limited 21/11/2014
3766 Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 06/11/2014
3767 Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 06/11/2014
3763 Stability of Extemporaneously Compounded Pyridoxine in Glass and Plastic Bottles and Plastic Syringes. Can J Hosp Pharm 03/11/2014
3761 Etude de la stabilité de solutions de prostaglandine E1 à 48 et 72 heures en vue d'une administration parentérale en continu à des patients de néonatalogie. Master en pharmacie - University of Geneva 29/10/2014
3758 Feasibility and stability of metaraminol in pre-filled syringes. J Pharm Pract and Res 10/10/2014
3759 Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compotibility of which ws indicated by the supplier. Yakugaku Zasshi 10/10/2014
3757 How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis? Antimicrob Agents Chemother 06/10/2014
3754 Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation. Int J Pharm Compound 05/10/2014
3755 Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition. Int J Pharm Compound 05/10/2014
3752 Dalbavancin (Dalvance®) - Summary of Product Characteristics Durata Therapeutics Holding 26/09/2014
3753 Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 26/09/2014
3743 The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles. Int J Pharm 25/09/2014
3745 Sodium chloride residue provides potential for drug incompatibiities. Am J Hosp Pharm 25/09/2014
3731 Thermal and photolytic decomposition of methotrexate in aqueous solutions. J Pharm Sci 18/09/2014
3728 Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 09/09/2014
3721 Belinostat®) - Summary of Product Characteristics Spectrum Pharmaceuticals 05/09/2014
3722 Stability of cilazapril in pediatric oral suspensions prepared from commercially available tablet dosage forms. Acta Pol Pharm 05/09/2014
3723 Stabilité des préparations extemporanées de doxapram (Doprams®) à usage néonatal. Archives de Pédiatrie 05/09/2014

Site créé par Cyril Labbé - Temps de calcul serveur : 89 millisecondes